EN DE
Watch Intelicare Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Intelicare Holdings (ICR) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Intelicare Holdings stock A$0.02, price A$0.02, upside +0.6%, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000081788

IH Intelicare Holdings logo Thin data Nov 10, 2026

Intelicare Holdings

ICR · AU
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value A$0.0171 · Fairly valued
Expensive Growth (revenue 5y +41.3 %/yr in AUD)
Quality 32/100
Loss-making · -102.7% net margin (TTM)
Negative free cash flow
Trails peers (2/8)
Narrow moat 12/100
Thin data
Estimate⚠ Thinly traded
Watch Intelicare Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.1250 A$0.0050 Fair Value A$0.0171 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0050 – A$0.1250 · fair‑value band A$0.0165 – A$0.0177 · the A$0.0170 price screens below the A$0.0171 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Intelicare in your weekly email

Every Wednesday you see whether Intelicare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Intelicare Holdings Limited engages in the research, development, and sale of predictive analytics hardware and software package for use in the aged care, disability, and health industries in Australia.

Show moreShow less

The company offers a smart home and predictive analytics platform for caregivers to track activity levels, patterns of behavior, health metrics, sleep, and others to detect and help prevent incidents, emergencies, and health issues.

It also provides hardware solutions, such as smart home sensors; a two-way voice hub that sends instant emergency alert to caregivers or a duress call triage service; emergency and incident detection devices, including pendants and panic buttons; and vitals and health metrics devices.

In addition, the company offers a smart platform for access to 24/7 live health and wellbeing data. Additionally, it engages in sales and marketing, and research and development activities. Intelicare Holdings Limited was founded in 2016 and is based in Leederville, Australia.

Stock analysis

Intelicare Holdings (ICR) currently trades at A$0.0170, while our estimate is A$0.0171, so the stock looks roughly fairly valued today (gap 0.6%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0165 (bear) to A$0.0177 (bull), the price of A$0.0170 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Intelicare Holdings reported revenue of A$2.0M in FY2026 versus A$430K in FY2022, a compound +47.6%/yr. Reported net income was −A$2.1M in FY2026.

Key figures

Market cap A$12.2M (≈ $8.4M) Micro · P/S ratio 7.01 · Net margin −103% · Return on equity −1,058% · Return on assets (EBIT) −175% (5-year average) · Operating margin −43.3% · Revenue (TTM) A$2.0M · Revenue growth (YoY) +241%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 43% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at 1%, ICR screens cheaper than that median.

Fair Value

Bear A$0.0165 Fair Value A$0.0171 Bull A$0.0177
Price A$0.0170 · Upside +0.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 68
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+113.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+71.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.3%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+120.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,351.4% (2021) → −125.1% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch ICR, get fair value alerts →

Compare Intelicare Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside +0.6% · Above median
Profitability
Return on assets −62.9% · Bottom 25%
Net margin (12 months) −102.7% · Bottom 25%
Operating margin (12 months) −43.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 240.6% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 9.89× · Priciest 25%
P/S (12 months) 5.96× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)34 · sector 13
FUTURE (revenue growth)100 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs ICR
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs ICR
HealthEquity, Inc HQY $103.54 $112.32 +8% vs ICR
Waystar Holding WAY $29.30 $29.10 −1% vs ICR
Tempus AI, Inc TEM $80.54 $52.58 −35% vs ICR
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs ICR
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs ICR
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs ICR
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs ICR
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs ICR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Intelicare Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Intelicare Holdings Fair Value". https://www.fairvalue-calculator.com/stock/ICR

Frequently asked questions

Is Intelicare Holdings (ICR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0171 versus a price of A$0.0170, about +1% upside (fairly valued).
What is the fair value of ICR?
Our estimate for Intelicare Holdings is A$0.0171 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0170.
What is the quality score of ICR?
Intelicare Holdings has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Intelicare Holdings (ICR)?
Our calculated price target is the estimate of A$0.0171 (as of Nov 10, 2026). Cautious scenario A$0.0165, optimistic scenario A$0.0177. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Intelicare Holdings stock forecast for 2026?
Our estimate puts fair value at A$0.0171, about +1% upside versus a price of A$0.0170 (fairly valued). Cautious scenario A$0.0165, optimistic scenario A$0.0177. The calculation is refreshed regularly with new filings.
What is the revenue of Intelicare Holdings (ICR)?
Intelicare Holdings reported trailing-twelve-month revenue of about A$2.0M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Intelicare Holdings (ICR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Intelicare Holdings it is A$0.0171 per share (as of Nov 10, 2026), against a price of A$0.0170.
Is Intelicare Holdings stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ICR trades below its calculated fair value: price A$0.0170, fair value A$0.0171, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ICR?
No. The price is what the market pays today (A$0.0170); the fair value is what the company's own numbers justify (A$0.0171). For Intelicare Holdings the two are A$0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is Intelicare Holdings worth?
The market values Intelicare Holdings at about A$12.2M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0170; our models calculate a fair value of A$0.0171 per share.
What do the bullish and bearish scenarios say about ICR?
Our models span a range for Intelicare Holdings: cautious scenario A$0.0165, base A$0.0171, optimistic A$0.0177 per share (as of Nov 10, 2026, price A$0.0170). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is ICR from its 52-week high?
Intelicare Holdings trades at A$0.0170, about 43% below its 52-week high of A$0.0300 and 21% above the low of A$0.0140 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0171 is for.
Which stocks are comparable to Intelicare Holdings?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Intelicare Holdings stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0170, calculated fair value A$0.0171 (+1%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Intelicare Holdings currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Intelicare Holdings (ICR)?
The closing price on Nov 11, 2026 was A$0.0170. Our estimate is A$0.0171, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Intelicare Holdings right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0165 to A$0.0177), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Intelicare Holdings

How large is the market capitalisation of Intelicare Holdings (ICR)?
The market capitalisation of Intelicare Holdings is A$12.2M (≈ $8.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Intelicare Holdings (ICR)?
The price-to-sales ratio of Intelicare Holdings is 7.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Intelicare Holdings (ICR)?
The net margin of Intelicare Holdings is −103% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Intelicare Holdings (ICR)?
The return on equity (ROE) of Intelicare Holdings is −1,058% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Intelicare Holdings (ICR)?
On an EBIT basis the return on assets of Intelicare Holdings is −175% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Intelicare Holdings (ICR)?
The operating margin of Intelicare Holdings is −43.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Intelicare Holdings (ICR)?
Revenue at Intelicare Holdings is growing +241% versus a year earlier (3y avg +71.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Intelicare Holdings (ICR) generate?
The free cash flow of Intelicare Holdings is −A$1.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Intelicare Holdings (ICR) hold?
Intelicare Holdings holds more cash than debt, A$2.2M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Intelicare Holdings in the live analysis

One click puts Intelicare Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.